Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.

Revenue
+4.97%
EPS
+731.9%
Free cash flow
+255.6%
Total debt
−9.48%

Quarter to September 2026, against a year earlier

25.57 0.93 −3.51%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
21.3×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100

Baxter International Inc. (BAX) EBITDA

Alert me on EBITDA

Baxter International Inc.'s EBITDA for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.5B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $2.6B (fiscal 2019); the current reading is higher than 27% of that period. Baxter International Inc. ranks 7th of 47 Medical Instruments & Supplies companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $1.4B (2.56%)
FY2024 $1.5B (12.12%)
FY2023 $1.7B 22.27%
FY2022 $1.4B (37.62%)
FY2021 $2.2B (9.73%)
FY2020 $2.5B (5.25%)
FY2019 $2.6B 10.06%
FY2018 $2.4B 15.55%
FY2017 $2.0B 31.91%
FY2016 $1.5B 27.90%

Quarterly newest first

Period EBITDA Change
Sep 2026 $464.0M 1.75%
Jun 2026 $456.0M 50.50%
Mar 2026 $303.0M 5.94%
Dec 2025 $286.0M (30.07%)
43 more quarters

Against its own ten years

Low $1.2B High $2.6B
Ten-year median $1.7B
Current reading's percentile 27

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on BAX